KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Discontinued OperationsCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in CashChange in IntangiblesChange in InventoryDepreciation & Amortization (CF)DivestmentsExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BioNTech SE (BNTX) Free Cash Flow (2018 - 2025)

Historic Free Cash Flow for BioNTech SE (BNTX) over the last 8 years, with Q3 2025 value amounting to $954.7 million.

  • BioNTech SE's Free Cash Flow rose 25355.43% to $954.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$42.5 million, marking a year-over-year decrease of 10218.0%. This contributed to the annual value of $528.1 million for FY2024, which is 9126.77% down from last year.
  • As of Q3 2025, BioNTech SE's Free Cash Flow stood at $954.7 million, which was up 25355.43% from $196.5 million recorded in Q2 2025.
  • BioNTech SE's Free Cash Flow's 5-year high stood at $4.9 billion during Q3 2022, with a 5-year trough of -$769.8 million in Q1 2025.
  • Over the past 5 years, BioNTech SE's median Free Cash Flow value was $941.0 million (recorded in 2023), while the average stood at $1.3 billion.
  • As far as peak fluctuations go, BioNTech SE's Free Cash Flow skyrocketed by 114400157497.58% in 2022, and later plummeted by 17379.26% in 2025.
  • Over the past 5 years, BioNTech SE's Free Cash Flow (Quarter) stood at $273.3 million in 2021, then skyrocketed by 260.55% to $985.4 million in 2022, then rose by 2.06% to $1.0 billion in 2023, then crashed by 142.15% to -$423.9 million in 2024, then skyrocketed by 325.2% to $954.7 million in 2025.
  • Its Free Cash Flow stands at $954.7 million for Q3 2025, versus $196.5 million for Q2 2025 and -$769.8 million for Q1 2025.